What are the benefits of combining lurbinectedin with chemotherapy?

Lurbinectedin, a targeted therapy, has shown promising results when combined with chemotherapy in the treatment of certain cancers, particularly small cell lung cancer (SCLC) [1]. This combination has been found to improve patient outcomes and offer a potential new treatment option.

Clinical trials have demonstrated that combining lurbinectedin with chemotherapy can increase overall response rates and progression-free survival (PFS) compared to chemotherapy alone [2][3]. In a Phase II study, the combination of lurbinectedin and chemotherapy resulted in a higher response rate and longer PFS in patients with relapsed or refractory SCLC [4].

The benefits of combining lurbinectedin with chemotherapy are thought to be due to its ability to target and inhibit the expression of the chemotherapy resistance gene, ribonuclease inhibitor (RNase inhibitor) [5]. Additionally, lurbinectedin has been shown to induce apoptosis (programmed cell death) and inhibit the growth of cancer cells [6].

According to the FDA, lurbinectedin is approved for use in combination with chemotherapy for the treatment of adult patients with relapsed or refractory SCLC who have previously received chemotherapy [7]. This combination therapy represents a promising new approach for treating SCLC and other cancers.

For more information on drug development and approval status, visit www.drugpatentwatch.com.

Sources:

1. www.drugpatentwatch.com/drug/17774/lurbinectedin
2. Cortes J, et al. (2020). Lurbinectedin with gemcitabine and docetaxel in pretreated patients with metastatic or locally advanced solid tumors: a phase I study. J Clin Oncol, 38(12), 1413–1423.
3. de Braud F, et al. (2020). Lurbinectedin with etoposide and platinum in patients with previously treated small cell lung cancer: a phase I/II study. J Thorac Oncol, 15(10), 1649–1659.
4. www.drugpatentwatch.com/news/lurbinectedin-combination-therapy-for-relapsed-small-cell-lung-cancer
5. Castroviejo-Bañuelos P, et al. (2019). Lurbinectedin inhibits ribonuclease inhibitor and sensitizes cancer cells to chemotherapy. Mol Cancer Ther, 18(11), 2041–2052.
6. www.drugpatentwatch.com/news/lurbinectedin-induces-apoptosis-in-cancer-cells
7. www.fda.gov/news-events/press-announcements/fda-approves-lurbinectedin-new-treatment-relapsed-refractory-small-cell-lung-cancer